We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

11 hedge funds and large institutions have $1.18M invested in Traws Pharma in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

13% less capital invested

Capital invested by funds: $1.36M → $1.18M (-$182K)

15% less funds holding

Funds holding: 13 → 11 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$349K
2
Renaissance Technologies
Renaissance Technologies
New York
+$63.4K
3
Deutsche Bank
Deutsche Bank
Germany
+$31.7K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$65K
2
Citigroup
Citigroup
New York
-$31.7K
3
UBS Group
UBS Group
Switzerland
-$31.7K
4
VKH
Virtu KCG Holdings
New York
-$31.7K
5
ARTA
A.R.T. Advisors
New York
-$28K

TRAW Hedge Fund Activity: Q1 2016 in Review

11 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2016, worth a combined $1.18M — down 13% from $1.36M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of TRAW and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $349K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $65K sold.

  • 11 institutional investors held Traws Pharma (TRAW) as of Q1 2016, down from 13 in Q4 2015.
  • Funds reported $1.18M of Traws Pharma stock for Q1 2016, down 13% quarter-over-quarter.
  • 3 funds opened new Traws Pharma positions in Q1 2016 and 4 closed out, a net change of -1 holder.
  • The largest Traws Pharma buyer in Q1 2016 was Anson Funds Management, an estimated $349K added.
  • The largest Traws Pharma seller in Q1 2016 was Jacobs Levy Equity Management, an estimated $65K sold.

Based on aggregated 13F filings for Q1 2016.